Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bioverativ Fills Gap In Pipeline With $400m True North Buy

Executive Summary

Bioverativ revealed its first transaction since spinning out from Biogen with the acquisition of True North for $400m plus up to $425m in milestone payments. The deal gives Bioverativ a clinical asset, helping to fill the gap between preclinical programs and commercial products in its R&D pipeline.


Related Content

Bioverativ: More Than Just A Hemophilia Company
Sanofi Builds Blood Disorder Specialty With Bioverativ Buy
Biopharma Quarterly Deal-Making Statistics, Q2 2017
Shire Discontinues Development Of Once-Weekly SHP656 For Hemophilia A
VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth
Patient Registries Prove Value As Drug Development Tools
INTERVIEW: Biogen's Danos on why now is gene therapy's time
1Q EARNINGS: BMS sees sales slide, plans nivolumab rolling BLA
BioNotebook: Sangamo/Biogen, Adamas/Forest, Zymeworks/Lilly, Sunesis
iPierian raises $30m to target tau, spin out complement program


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts